Session I: September 7, 2022

Understanding and Addressing the Impact of COVID-19 on the Prostate Cancer Racial Disparity

During the COVID-19 pandemic prostate cancer early detection screenings and treatments were delayed. This session will examine how Black patients were impacted compared to other patients. It will also examine the challenges faced today in catching up while handling the dramatic increase in the number of new prostate cancer cases estimated by the American Cancer Society (ACS). The ACS estimated a 30% increase in new prostate cancer cases in 2021 and an additional 8% increase for 2022 for 268,490 new cases in 2022 alone. This is the largest increase of new cases for any of the four major cancers.

Prior Summit Images

Welcome and Opening Remarks: Mr. Thomas Farrington, President and Founder, PHEN

Moderator: J. Jacques Carter, MD, MPH, Assistant Professor of Medicine, Harvard Medical School

Prostate Cancer New Cases Overview from American Cancer Society (ACS)

Keith Crawford, MD, PhD, Director of Clinical Trials and Patient Education, PHEN

An Assessment of Prostate Cancer Treatment Among Black and White Patients During the COVID-19 Pandemic

Adrien Bernstein, MD, MS, Urologic Oncologist, Albany Medical College, Albany, NY

Benefits of PSA Prostate Cancer Screening Found to Be More Favorable than Previous Estimates, Especially for Blacks

Jim Hu, MD, MPH, Urologic Oncologist, Weill Cornell Medicine, New York, NY

Panel Discussion with Q&A:

The session presenters will be joined by other leaders to discuss the impact of the COVID-19 pandemic on the prostate cancer racial disparity.

Keith Crawford, MD, PhD

Adrien Bernstein, MD, MS

Jim Hu, MD, MPH

Closing Remarks: Mr. Thomas Farrington